[Comment] Potential efficacy of interleukin-1 β inhibition in lung cancer
Over the past two decades, a wealth of experimental and clinical data have intimately linked dysregulated production of the potent proinflammatory cytokine interleukin 1 β with several chronic inflammatory and autoimmune diseases, of which the most evidence is available for rheumatoid arthritis and cardiovascular disease (eg, atherosclerosis).1–3 Notably, these disease associations have provided the impetus to develop clinical grade inhibitors against interleukin 1β or its receptor, with the intereukin-1-receptor antagonist anakinra being the first such inhibitor approved for clinical use (in 2001).
Source: LANCET - Category: General Medicine Authors: Brendan J Jenkins Tags: Comment Source Type: research
More News: Arthritis | Autoimmune Disease | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | General Medicine | Heart | Lung Cancer | Rheumatoid Arthritis | Rheumatology